ZYAN 1Alternative Names: ZYAN-1; ZYAN1-1001
Latest Information Update: 08 Oct 2015
At a glance
- Originator Cadila Healthcare
- Class Antianaemics
- Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Anaemia
Most Recent Events
- 06 Feb 2015 Cadila plans a phase I trial for Anaemia (In volunteers) in India (PO)
- 28 Oct 2014 Phase-I clinical trials in Anaemia (In volunteers) in Australia (PO)